A shot of JD

“The foundation’s decision to drastically reduce its exposure to health-related stocks is striking, as many of its charity grants have been disbursed to address developing country health issues. Its move comes against the background of anxiety among drugmakers and healthcare insurance firms about the potential impact of the Obama administration’s proposed overhaul of the U.S. healthcare system, which could put pressure on prescription drug prices.”